The Goldman Sachs Group started coverage on shares of Privia Health Group (NASDAQ:PRVA – Get Rating) in a research note issued to investors on Friday, The Fly reports. The brokerage set a "buy" rating and a $32.00 price target on the stock. The Goldman Sachs Group's target price would indicate a potential upside of 15.52% from the stock's previous close.

Other equities research analysts have also issued research reports about the stock. UBS Group assumed coverage on shares of Privia Health Group in a research note on Thursday, December 8th. They set a "buy" rating and a $30.00 price objective on the stock. Truist Financial decreased their price objective on shares of Privia Health Group to $41.00 in a report on Thursday, November 17th. SVB Leerink cut their target price on Privia Health Group from $46.00 to $39.00 and set an "outperform" rating for the company in a research report on Friday, November 11th. Piper Sandler dropped their price target on shares of Privia Health Group to $42.00 in a research report on Thursday, November 17th. Finally, BTIG Research decreased their target price on Privia Health Group from $45.00 to $40.00 in a research report on Monday, January 9th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Privia Health Group presently has a consensus rating of "Buy" and an average price target of $38.93.

Privia Health Group Price Performance

Shares of PRVA stock opened at $27.70 on Friday. The firm has a market capitalization of $3.17 billion, a P/E ratio of -76.94 and a beta of 0.81. The company's fifty day moving average price is $24.08 and its two-hundred day moving average price is $31.07. Privia Health Group has a 12 month low of $17.99 and a 12 month high of $44.64.

Insider Buying and Selling at Privia Health Group

In other news, Director William M. Sullivan sold 18,153 shares of the firm's stock in a transaction on Friday, November 11th. The shares were sold at an average price of $27.56, for a total value of $500,296.68. Following the sale, the director now owns 6,172,493 shares in the company, valued at $170,113,907.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director William M. Sullivan sold 12,115 shares of the firm's stock in a transaction on Friday, January 6th. The stock was sold at an average price of $21.24, for a total value of $257,322.60. Following the completion of the transaction, the director now directly owns 5,832,968 shares of the company's stock, valued at $123,892,240.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William M. Sullivan sold 18,153 shares of the firm's stock in a transaction on Friday, November 11th. The stock was sold at an average price of $27.56, for a total value of $500,296.68. Following the completion of the transaction, the director now directly owns 6,172,493 shares of the company's stock, valued at $170,113,907.08. The disclosure for this sale can be found here. Insiders have sold a total of 3,583,757 shares of company stock worth $81,067,912 over the last 90 days. Insiders own 57.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Assetmark Inc. raised its holdings in shares of Privia Health Group by 119.4% in the second quarter. Assetmark Inc. now owns 893 shares of the company's stock valued at $26,000 after buying an additional 486 shares during the last quarter. Signaturefd LLC bought a new stake in shares of Privia Health Group during the 3rd quarter worth approximately $32,000. First Horizon Advisors Inc. raised its stake in shares of Privia Health Group by 4,330.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,019 shares of the company's stock worth $29,000 after purchasing an additional 996 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Privia Health Group during the 2nd quarter worth approximately $46,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Privia Health Group during the 1st quarter worth approximately $47,000. 66.83% of the stock is owned by institutional investors.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Articles

• Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
• Ford Stock Going Forward After Big Earnings Flop
• Insiders And Institutions Buy Wolverine Worldwide
• Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
• Bright Green Corporation Future May be Getting Brighter
• Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.